TARGETING EXHAUSTED CYTOTOXIC T CELLS BY CTLA-4 BLOCKADE PROMOTES ELIMINATION OF NEOPLASTIC CELLS IN HUMAN MYELOFIBROSIS XENOGRAFTS

EHA Library, Lara Tavernari, 419087

THE EFFECT OF METHYLATION ON THE LET-7-BCL-XL-BCL2 AXIS AND THE POTENTIAL USE OF BH3 MIMETIC DRUGS IN HISTIOCYTIC NEOPLASMS

EHA Library, Oshrat Hershkovitz-Rokah, 419088

EFFICACY OF INCA033989 IN CHRONIC AND ADVANCED FORMS OF CALRDEL52 AND CALRINS5 MYELOPROLIFERATIVE NEOPLASMS (MPN) MODELS

EHA Library, Isabelle Plo, 419089

THE ATYPICAL CHEMOKINE RECEPTOR CCRL2 IS UPREGULATED AND PROMOTES INTERFERON-GAMMA SIGNALING IN ADVANCED MYELOPROLIFERATIVE NEOPLASMS.

EHA Library, Theodora Chatzilygeroudi, 419090

UMBILICAL CORD MESENCHYMAL STROMAL CELLS AMELIORATE MYELOFIBROSIS IN VIVO.

EHA Library, Chien-Chin Lin, 419091

TAGRAXOFUSP EXHIBITS ANTITUMORAL ACTIVITY IN PRECLINICAL MODELS OF MYELOFIBROSIS AND ENHANCES ANTILEUKEMIC ACTIVITY OF JAK INHIBITORS

EHA Library, Vittoria Nicolis di Robilant, 419092

ADVANCING EARLY DETECTION AND IMPROVED TARGETED THERAPY IN MYELOPROLIFERATIVE NEOPLASMS: INSIGHTS FROM MULTIMODAL IMAGING AND NANOPARTICLE-MEDIATED DRUG DELIVERY

EHA Library, Julian Baumeister, 419093

SINGLE CELL MULTIOMICS IDENTIFIES ABERRANT COMMUNICATION BETWEEN DENDRITIC CELLS AND LEUKAEMIA STEM CELLS AS A THERAPEUTICALLY TARGETABLE AXIS IN JUVENILE MYELOMONOCYTIC LEUKAEMIA

EHA Library, Eleni Louka, 419094

TARGETED T CELLS AGAINST HEMATOPOIETIC CELLS EXPRESSING ONCOGENIC CALRETICULIN MUTANTS

EHA Library, Robert Kralovics, 419095

TET2 ADDITIONAL MUTATIONS AT DIAGNOSIS IMPACT THE RESPONSE OF FIRST-LINE TREATMENT WITH HYDROXYUREA OR INTERFERON-Α IN ESSENTIAL THROMBOCYTHEMIA

EHA Library, Carole Mosnier, 419096

ESTABLISHMENT OF A NOVEL PRECLINICAL MOUSE MODEL FOR ADVANCED SYSTEMIC MASTOCYTOSIS

EHA Library, Martina Konantz, 419097

IMPACT OF GENETIC BACKGROUND ON THE FIBROTIC TRANSFORMATION IN MURINE MPN-MODELS

EHA Library, Yu-An Lin, 419098

REAL WORLD PRACTICE REVEALS SERUM TNFΑ AS THE EARLY PROGNOSTIC PREDICTOR FOR MYELOFIBROSIS WITH RUXOLITINIB TREATMENT

EHA Library, Xinjie Chen, 419099

RKER-050, A MODIFIED ACTIVIN RECEPTOR TYPE IIA LIGAND TRAP, RESCUED ANEMIA AND INCREASED MUSCLE MASS AND STRENGTH IN A MOUSE MODEL OF MYELOFIBROSIS

EHA Library, Blake Moses, 419100

MONOCYTES WITH HIGHER EXPRESSION OF CD38 ACCELERATE MYELOFIBROSIS IN MPN

EHA Library, Yiru Yan, 419101

COMPLEX ALTERNATIVE SPLICING AND RELATED NEOANTIGEN PATTERNS IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Jing Sun, 419102

IMMUNOPHENOTYPIC ANALYSIS OF PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS RECEIVING THERAPY WITH THE BET INHIBITOR PELABRESIB

EHA Library, Rosa Andres Ejarque, 419103

T-CELL PHENOTYPING SUPPORTS THE USE OF T-CELL ENGAGING ANTIBODIES FOR TREATMENT OF CALRETICULIN MUTATED MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Anna Kuchnio, 419104

CDK8/19 INHIBITION: A PROMISING THERAPEUTIC STRATEGY IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Zachary Zaroogian, 419105

ALK2 AND JAK2 INHIBITION FOR IMPROVED TREATMENT OF ANEMIA IN MYELOFIBROSIS PATIENTS: PRECLINICAL PROFILE OF AN ALK2 INHIBITOR ZILURGISERTIB IN COMBINATION WITH RUXOLITINIB

EHA Library, Ricardo Macarron, 419106

FEDRATINIB INHIBITS IMMUNE EVASION AND RESTORES B CELL MATURATION: BIOMARKER ANALYSIS FROM THE FREEDOM2 STUDY

EHA Library, Claire HARRISON, 419107

EFFECT OF NOVEL AGENTS ON THE MECHANISM OF FIBROCYTE-MEDIATED INDUCTION OF MYELOFIBROSIS

EHA Library, Takaaki Maekawa, 419108

INFLAMMATION NOT HAEMATOPOIESIS CAUSES SPLENOMEGALY IN A MOUSE MODEL OF POLYCYTHAEMIA VERA.

EHA Library, Cavan Bennett, 419109

EXPRESSION OF GERMLINE JAK2 R1063H REPRESENTS INCREASED RISK OF THROMBOSIS AND IMPAIRS NORMAL HEMATOPOIETIC DEVELOPMENT IN MICE

EHA Library, Veronika Zimolova, 419110

MIR-93 ATTENUATES CALR MUTANT-DRIVEN ONCOGENIC ACTIVITY IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Chih-Cheng Chen, 419111

HUMANIZED IMMUNOCOMPETENT MOUSE MODEL FOR THE PRECLINICAL THERAPEUTIC EVALUATION OF T CELL ENGAGING BISPECIFIC ANTIBODIES TARGETING CALRETICULIN MUTANT MPN

EHA Library, Shengen Xiong, 419112

DUPLICATION OF CHROMOSOME 9P INDUCES T CELL EXHAUSTION AND INCREASED CLONOGENICITY OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IN JAK2-MUTANT MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Ruggiero Norfo, 419113

MUTATIONAL LANDSCAPE OF PATIENTS ENROLLED IN THE LOW-PV TRIAL WITH ROPEGINTERFERON ALFA-2B

EHA Library, Paola Guglielmelli, 419114

PRECLINICAL EVALUATION OF INCB160058 - A NOVEL AND POTENTIALLY DISEASE-MODIFYING THERAPY FOR JAK2V617F MUTANT MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Hamza Celik, 419115

CALRETICULIN AND JAK2V617F DRIVER MUTATIONS INDUCE DISTINCT MITOTIC DEFECTS IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Daniel Moreno-Andrés, 419116

PROGRESSION TO MYELOFIBROSIS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA: AN ANALYSIS FROM THE PROSPECTIVE MOST STUDY

EHA Library, Ruben Mesa, 419117

UNVEILING THE EFFECTIVENESS AND PREDICTIVE FACTORS OF JAKTINIB TREATMENT IN MYELOFIBROSIS PATIENTS WITH ANEMIA

EHA Library, Huafeng Wang, 419118

THROMBOSIS RATES FOR MPN PATIENTS BY ATTAINED AGE AND TIME SINCE DIAGNOSIS: A SWEDISH REGISTER-BASED MATCHED-COHORT STUDY

EHA Library, Nurgul Batyrbekova, 419119

IMPACT OF TP53 MUTATION ALLELIC BURDEN ON OUTCOME OF PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: A STUDY FROM COMMAND CONSORTIUM.

EHA Library, Talha Badar, 419120

PATIENT CHARACTERISTICS, TREATMENT PATTERNS, AND HEALTH OUTCOMES IN A REAL-WORLD POPULATION OF PATIENTS WITH MYELOFIBROSIS TREATED WITH FEDRATINIB

EHA Library, Francesco Passamonti, 419121

DECIPHERING THE PREDICTORS OF DEATH IN POLYCYTHEMIA VERA: FOCUS ON THE NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) AND THE INCIDENCE OF ARTERIAL THROMBOSIS

EHA Library, Tiziano Barbui, 419122

AGE-DEPENDENT LINK BETWEEN ARTERIAL THROMBOSIS AND SECONDARY CANCER IN PH-NEG MPN: CASE-CONTROL STUDY INSIGHTS

EHA Library, Tiziano Barbui, 419123

EFFICACY OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS WHO HAVE OVERLAPPING THROMBOCYTOPENIA AND ANEMIA

EHA Library, Pankit Vachhani, 419124

REAL-WORLD DATA ON DIRECT ORAL ANTICOAGULANTS IN BCR::ABL1-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS: A MULTICENTER STUDY ON BEHALF OF SUBCOMMITTEE ON MPNS FOR TURKISH SOCIETY OF HEMATOLOGY

EHA Library, Mehmet Baysal, 419125

LONG TERM FOLLOW-UP RESULTS OF PHASE II CLINICAL TRIAL EVALUATING RUXOLITINIB (RUX) AND AZACITIDINE (AZA) COMBINATION THERAPY IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)

EHA Library, Sankalp Arora, 419126

CALRETICULIN MUTATIONS INFLUENCE RESPONSE AND OUTCOME IN TRANSPLANT-AGE MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB

EHA Library, Francesca Palandri, 419127

REVISED “IRR6” MODEL IN INTERMEDIATE-1 RISK MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB

EHA Library, Francesca Palandri, 419128

A PHASE 2 STUDY OF PEMIGATINIB (FIGHT-203; INCB054828) IN PATIENTS WITH MYELOID/LYMPHOID NEOPLASMS WITH FIBROBLAST GROWTH FACTOR RECEPTOR 1 GENE REARRANGEMENT

EHA Library, Alessandro Vannucchi, 419129

RUXOLITINIB STARTING DOSE REDUCTION AFFECT OVERALL SURVIVAL IN MYELOFIBROSIS: AIFA MONITORING REGISTRIES ANALYSIS

EHA Library, Massimo Breccia, 419130

THE IMPACT OF NEW OR WORSENING ANEMIA ON CLINICAL OUTCOMES IN 2233 PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB: RESULTS FROM THE EXPANDED-ACCESS JUMP STUDY

EHA Library, Haifa Kathrin Al-Ali, 419131

ANALYSIS OF CARDIOVASCULAR RISK IN 920 PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS USING NATURAL LANGUAGE PROCESSING

EHA Library, Andrea Duminuco, 419132

IMPACT OF CALR MUTATION TYPE AND NON-DRIVER MUTATIONS ON THE RESPONSE TO CYTOREDUCTIVE TREATMENT AND OUTCOMES IN PATIENTS INCLUDED IN THE SPANISH REGISTRY OF ESSENTIAL THROMBOCYTHEMIA (RETE)

EHA Library, Marta Santaliestra Tomas, 419133

A REAL-WORLD EVALUATION OF RISK FACTORS FOR DISEASE PROGRESSION IN PATIENTS WITH POLYCYTHEMIA VERA (PV) ENROLLED IN REVEAL

EHA Library, Michael Grunwald, 419134

THE TRIPLE A MODEL-AAA (AGE, ABSOLUTE NEUTROPHIL COUNT, ABSOLUTE LYMPHOCYTE COUNT) PREDICTS SURVIVAL AND THROMBOSIS IN POLYCYTHEMIA VERA

EHA Library, Ivan Krecak, 419135

RUXOLITINIB TREATMENT IN PATIENTS WITH POLYCYTHEMIA VERA REDUCES JAK2 ALLELE BURDEN AND IMPROVES HEMATOCRIT CONTROL AND SYMPTOM BURDEN

EHA Library, Claire HARRISON, 419136

NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IN POLYCYTHEMIA VERA (PV): CORRELATION WITH ROPEG-INTERFERON RESPONSE IN LOW PV TRIAL

EHA Library, Tiziano Barbui, 419137

FEDRATINIB IN PATIENTS WITH MYELOFIBROSIS EXPOSED TO RUXOLITINIB: AN INDIRECT TREATMENT COMPARISON WITH MOMELOTINIB AND PACRITINIB

EHA Library, Francesca Palandri, 419138

INTERMEDIATE-1 RISK MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: PREDICTORS OF RESPONSE AND OUTCOME MAY DRIVE TRANSPLANT DECISION

EHA Library, Francesca Palandri, 419139

HIGH RATE OF DISEASE PROGRESSION IN PATIENTS WITH LOW-RISK MYELOFIBROSIS (MF) ENROLLED IN THE PROSPECTIVE MOST STUDY

EHA Library, Michael Grunwald, 419140

COMPREHENSIVE EVALUATION OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS: FINAL ANALYSIS RESULTS FROM A RANDOMIZED PHASE 3 STUDY

EHA Library, Huafeng Wang, 419141

SYMPTOM-FOCUSED RESULTS FROM SUMMIT PART 1: AN ONGOING, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL OF BEZUCLASTINIB IN ADULT PATIENTS WITH NONADVANCED SYSTEMIC MASTOCYTOSIS

EHA Library, Lindsay Rein, 419142

HIGH RESOLUTION CHEST COMPUTED TOMOGRAPHY RESPONSES FOR A COHORT OF ADULT WITH PULMONARY LANGERHANS CELL HISTIOCYTOSIS

EHA Library, Long Chang, 419143

A NEW MACHINE LEARINING CLINICAL SCORE FOR THROMBOSIS RISK IN POLYCYTHEMIA VERA: THROMBOVERA CS

EHA Library, Isidora Arsenović, 419144

‘REAL WORLD ANALYSIS APPLYING INTERNATIONAL PROGNOSTIC SCORE (IPSM) IN NON-ADVANCED SYSTEMIC MASTOCYTOSIS PATIENTS IN UK SINGLE CENTRE OF EXCELLENCE’

EHA Library, Priya Sriskandarajah, 419145

A PHASE 1B TRIAL OF DISC-0974, AN ANTI-HEMOJUVELIN ANTIBODY, IN PATIENTS WITH MYELOFIBROSIS AND ANEMIA

EHA Library, Naseema Gangat, 419146

THE ACTIVIN RECEPTOR-LIKE KINASE-2 INHIBITOR ZILURGISERTIB (INCB000928) AS MONOTHERAPY OR WITH RUXOLITINIB IN PATIENTS WITH ANEMIA DUE TO MYELOFIBROSIS: PHASE 1/2 STUDY RESULTS

EHA Library, Prithviraj Bose, 419147

RECOGNITION OF SYMPTOM BURDEN IN MPN: DISCREPANCIES BETWEEN  PATIENT- AND PHYSICIAN-REPORTED ASSESSMENT – AN INTRA-INDIVIDUAL ANALYSIS BY THE GERMAN MPN STUDY GROUP (GSG-MPN)

EHA Library, Susanne Isfort, 419148

PROGNOSTIC IMPACT OF LEUKOCYTOSIS, MONOCYTOSIS AND EOSINOPHILIA IN ADVANCED SYSTEMIC MASTOCYTOSIS: A REGISTRY-BASED ANALYSIS OF THE GREM

EHA Library, Johannes Lübke, 419149

EVALUATING MYELODYSPLASIA RELATED MUTATIONS BY ELN 2022 CLASSIFICATION AND IT IMPACT ON ACCELERATED PHASE AND BLAST PHASE MYELOPROLIFERATIVE NEOPLASMS.

EHA Library, Verna Cheung, 419150

CLINICAL AND MOLECULAR CHARACTERISATION OF PATIENTS WITH LOW JAK2V617F ALLELE BURDEN: INSIGHTS FROM LONGITUDINAL FOLLOW-UP

EHA Library, Nieves Garcia-Gisbert, 419151

BROMODOMAIN AND EXTRA-TERMINAL (BET) INHIBITOR INCB057643 IN PATIENTS WITH RELAPSED OR REFRACTORY MYELOFIBROSIS (MF) AND OTHER ADVANCED MYELOID NEOPLASMS: A PHASE 1 STUDY

EHA Library, Pankit Vachhani, 419152

IMPACT OF GENETIC FACTORS IN THE OVERALL SURVIVAL OF PATIENTS WITH CALR-MUTATED MYELOFIBROSIS

EHA Library, Ruth Stuckey, 419153

REAL-WORLD OUTCOMES OF MOMELOTINIB AS AN ALTERNATIVE THERAPY TO OTHER JAK INHIBITORS IN MYELOFIBROSIS PATIENTS WITH ANEMIA.

EHA Library, Valentin Garcia-Gutierrez, 419154

CPH DEEP NEURAL NETWORK AND CONTINUOUS-TIME MULTI-STATE MARKOV CHAIN MODELS CONFIRM HMA TO BE THE BEST FIRST LINE TREATMENT OPTION FOR CMML PATIENTS – AN INTERNATIONAL STUDY COORDINATED BY THE AGMT

EHA Library, Lisa Pleyer, 419155

SELINEXOR PLUS RUXOLITINIB IMPACT ON SYMPTOM BURDEN IN PATIENTS WITH MYELOFIBROSIS AND POTENTIAL MECHANISM OF ACTION VIA INHIBITION OF NF-ΚB AND ACTIVATION OF P53 PATHWAYS

EHA Library, Srinivas Tantravahi, 419156

LENALIDOMIDE AND DEXAMETHASONE FOR ROSAI-DORFMAN DISEASE: A SINGLE ARM, SINGLE CENTER, PROSPECTIVE PHASE 2 STUDY

EHA Library, Long Chang, 419157

CLINICAL PATTERNS AND THERAPEUTIC CONSIDERATIONS IN MALIGNANT HISTIOCYTOSES: A NATIONWIDE RETROSPECTIVE ANALYSIS

EHA Library, Camille Bigenwald, 419158

REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH MYELOFIBROSIS TREATED WITH PACRITINIB IN THE UNITED STATES

EHA Library, John Mascarenhas, 419159

PREVALENCE OF POLYCYTHEMIA VERA, CYTOREDUCTIVE TREATMENT, AND THROMBOEMBOLIC EVENTS IN AFFECTED PATIENTS: A STUDY BASED ON LONGITUDINAL GERMAN HEALTH CLAIMS DATA

EHA Library, Haifa Al-Ali, 419160

IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH SECONDARY MYELOFIBROSIS

EHA Library, Nico Gagelmann, 419161

GERMLINE INACTIVATING VARIANTS IN SH2B3 DEFINE A NOVEL DISORDER CHARACTERIZED BY A TRANSIENT NEONATAL/INFANCY MYELOPROLIFERATIVE DISORDER AND SUBSEQUENT DEVELOPMENT OF THROMBOCYTOSIS IN CHILDHOOD

EHA Library, Davide Leardini, 419162

DECIPHERING THROMBOTIC COMPLICATIONS AND INFLAMMATORY FACTORS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS AND ATRIAL FIBRILLATION: A MULTI-CENTRE RETROSPECTIVE STUDY

EHA Library, Olga Chyrko, 419163

ENHANCING ACCURACY AND SAFETY OF AI-BASED BONE MARROW ASSESSMENT IN MPNS WITH AN AUTOMATED QUALITY CONTROL PIPELINE

EHA Library, Xuezi Hu, 419164

ADVANCED-STAGE HODGKIN LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX (A-HIPI) IN TURKISH CLASSICAL HODGKIN LYMPHOMA PATIENTS: A SINGLE-CENTER RETROSPECTIVE STUDY

EHA Library, Oguzhan Koca, 419165

TREATMENT OF ADVANCED STAGE, HIGH RISK SCORE HODGKIN'S DISEASE PATIENTS WITH CONVENTIONAL CHEMOTHERAPY PLUS BRENTUXIMAB VEDOTIN AND NIVOLUMAB: A PHASE II TRIAL RESULTS

EHA Library, Maher Salamoon, 419166

BRENTUXIMAB VEDOTIN (BV)+AVD IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA: AN ITALIAN REAL-LIFE MULTICENTRIC STUDY

EHA Library, Giovanni Manfredi Assanto, 419167

GERIATRIC FITNESS AND REAL-LIFE OUTCOMES IN ELDERLY PATIENTS WITH HODGKIN’S LYMPHOMA

EHA Library, Silvio Ligia, 419168

CONGESTIVE HEART FAILURE FOLLOWING ANTHRACYCLINE-CONTAINING TREATMENT FOR CLASSICAL HODGKIN LYMPHOMA: A SWEDISH MATCHED COHORT STUDY

EHA Library, Sissel Johanne Godtfredsen, 419169

PEMBROLIZUMAB PLUS THE ANTI–LAG-3 ANTIBODY FAVEZELIMAB FOR HEAVILY PRETREATED ANTI–PD-1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL): AN UPDATED ANALYSIS OF A PHASE 1/2 STUDY

EHA Library, Gareth Gregory, 419170

LONG-TERM CAUSE-SPECIFIC MORTALITY IN A COHORT OF 1,435 HODGKIN LYMPHOMAS TREATED AT THE NATIONAL ADULT PUBLIC CANCER PROGRAM IN CHILE OVER A 30-YEAR PERIOD

EHA Library, Massimo Federico, 419171

EVALUATION OF GONADAL FUNCTION IN YOUNG MEN AND WOMEN DIAGNOSED WITH HODGKIN LYMPHOMA

EHA Library, ANGELIKI GEORGOPOULOU, 419172

BENDAMUSTINE AND ADCETRIS IN UNTREATED HODGKIN LYMPHOMA OF THE ELDERLY: LONG-TERM RESULTS OF THE HALO TRIAL

EHA Library, Andrea Gallamini, 419173

PEMBROLIZUMAB PLUS THE ANTI–LAG-3 ANTIBODY FAVEZELIMAB FOR ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA: AN UPDATED ANALYSIS OF A PHASE 1/2 STUDY

EHA Library, Peter Borchmann, 419174

KEYNOTE-667: RESULTS FROM THE PHASE 2 STUDY OF PEMBROLIZUMAB (PEMBRO) IN CHILDREN AND YOUNG ADULTS WITH LOW-RISK CLASSICAL HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE (SER) TO FRONT-LINE CHEMOTHERAPY

EHA Library, Lisa Giulino-Roth, 419175

RADIOTHERAPY-FREE TREATMENT IN GOOD PROGNOSIS EARLY-STAGE HODGKIN LYMPHOMA (RAFTING TRIAL-NCT ID.04866654). RESULTS OF PATIENT STRATIFICATION.

EHA Library, Jan Maciej Zaucha, 419176

INNOVATIVE EVA REGIMEN (ETOPOSIDE, VINBLASTINE, DOXORUBICIN) IN HODGKIN'S LYMPHOMA TREATMENT FOR PREGNANT WOMEN.

EHA Library, Joanna Romejko-Jarosińska, 419177

DATA REQUIREMENTS FOR DEVELOPMENT OF PREDICTION MODELS FOR SURVIVAL AMONG HODGKIN LYMPHOMA PATIENTS: HOW MANY PATIENTS ARE NEEDED?

EHA Library, Rasmus Rask Kragh Jørgensen, 419178

BASELINE PET-CT RADIOMICS PREDICT 5-YEAR PROGRESSION FREE SURVIVAL IN ADVANCED STAGE HODGKIN LYMPHOMA

EHA Library, Fer de Wit, 419179

BRENTUXIMAB VEDOTIN - ESHAP SIGNIFICANTLY INCREASES THE METABOLIC COMPLETE REMISSION RATE VERSUS ESHAP IN RELAPSED CLASSICAL HODGKIN’S LYMPHOMA. FINAL RESULTS OF THE BRESELIBET PROSPECTIVE TRIAL.

EHA Library, Anna Sureda Balari, 419180

EARLY DETECTION OF CLASSIC HODGKIN LYMPHOMA RELAPSE USING ROUTINE SERUM TARC MEASUREMENTS DURING FOLLOW-UP

EHA Library, Sophie Teesink, 419181

ANIMATE: A UK PHASE II PET RESPONSE-ADAPTED TRIAL OF NIVOLUMAB IN RELAPSED / REFRACTORY CLASSICAL HODGKIN LYMPHOMA

EHA Library, Graham Collins, 419182

BRENTUXIMAB-VEDOTIN PLUS AVD CHEMOTHERAPY AS FRONTLINE THERAPY IN PATIENTS WITH STAGE IV CLASSICAL HODGKIN LYMPHOMA: A REAL-WORLD REPORT ON FEASIBILITY, EFFICACY AND INTERIM-PET RESULTS

EHA Library, Chiara Rusconi, 419183

KEYNOTE-667: UPDATED RESULTS FROM THE PHASE 2 STUDY OF PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH HIGH-RISK CLASSICAL HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE (SER) TO FRONT-LINE CHEMOTHERAPY

EHA Library, Christine Mauz-Koerholz, 419184

THE ADDITIONAL PROGNOSTIC VALUE OF ΔSUVMAX TO THE FIRST-LINE TREATMENT OF CLASSICAL HODGKIN LYMPHOMA

EHA Library, Laszlo Pinczes, 419185

HISTOLOGICAL GRADING OF NODULAR SCLEROSIS CLASSICAL HODGKIN LYMPHOMA (NSHL) RETAINS PROGNOSTIC SIGNIFICANCE WITHIN THE MODERN THERAPEUTIC LANDSCAPE

EHA Library, Alessandro Cellini, 419186